Dufour, Jean-François (2014). Hepatocellular carcinoma: sorafenib: for once age is not an issue. Nature reviews - gastroenterology & hepatology, 11(5), pp. 273-274. Nature Publishing Group 10.1038/nrgastro.2014.48
Full text not available from this repository. (Request a copy)Are some patients with hepatocellular carcinoma just too old to be treated? More specifically, should the age of a patient influence the way sorafenib is prescribed? A new study has tried to address these questions, providing helpful information to guide clinicians making these decisions.
Item Type: |
Journal Article (Further Contribution) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology |
UniBE Contributor: |
Dufour, Jean-François |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1759-5045 |
Publisher: |
Nature Publishing Group |
Language: |
English |
Submitter: |
Lilian Karin Smith-Wirth |
Date Deposited: |
20 Apr 2015 15:15 |
Last Modified: |
05 Dec 2022 14:45 |
Publisher DOI: |
10.1038/nrgastro.2014.48 |
PubMed ID: |
24686265 |
URI: |
https://boris.unibe.ch/id/eprint/67296 |